Keele Research Repository

Article

Rebbeck, T, Evans, K, Ferreira, P, Beales, D, Sterling, M, Bennell, KL, Cameron, I, Nicholas, M, Ritchie, C, Jull, G, Treleaven, J, Trevena, L, Refshauge, K, Connelly, L, Foster, NE ORCID: https://orcid.org/0000-0003-4429-9756, Black, D, Hodges, P, Ferreira, M, Shaw, TJ and Simic, M (2021) Implementation of a novel stratified PAthway of CarE for common musculoskeletal (MSK) conditions in primary care: protocol for a multicentre pragmatic randomised controlled trial (the PACE MSK trial). BMJ Open, 11 (12).

Schmid, P, Zaiss, M, Harper-Wynne, C, Ferreira, M, Dubey, S, Chan, S, Makris, A, Nemsadze, G, Brunt, AM, Kuemmel, S, Ruiz, I, Perelló, A, Kendall, A, Brown, J, Kristeleit, H, Conibear, J, Saura, C, Grenier, J, Máhr, K, Schenker, M, Sohn, J, Lee, KS, Shepherd, CJ, Oelmann, E, Sarker, S-J, Prendergast, A, Marosics, P, Moosa, A, Lawrence, C, Coetzee, C, Mousa, K and Cortés, J (2019) Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer. JAMA Oncology, 5 (11). 1556 - 1556.

Conference or Workshop Item

Schmid, P, Zaiss, M, Harper-Wynne, C, Ferreira, M, Dubey, S, Chan, S, Makris, A, Nemsadze, G, Brunt, AM, Kuemmel, S, Cabrero, IR, Perello, A, Kendall, A, Brown, J, Kristeleit, H, Conibear, J, Saura, C, Grenier, J, Mahr, K, Schenker, M, Sohn, JH, Lee, KS, Sarker, S-J, Coetzee, C, Mousa, K and Castan, JC (2018) MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer. In: 2017 San Antonio Breast Cancer Symposium, December 5-9 2017, San Antonio, Texas.